Scil Proteins Signs Research Project for Cancer Therapies

German biopharma Scil Proteins signed a collaboration with the Martin Luther University Halle-Wittenberg to develop therapies for gastrointestinal tumours.

German biotech company Scil Proteins has signed an agreement with the Martin Luther University Halle-Wittenberg to jointly work on new therapies for gastrointestinal tumours.

The project will be run by Professor Thomas Seufferlein, head of the University Hospital’s gastroenterology clinic, and will focus on the discovery and characterisation of disease-related molecular structures.

Scil Proteins will use its proprietary Affilin platform to identify effective therapeutics and advance them into further clinical development.

Scil Proteins’ Affilin therapeutics are scaffold proteins derived from the human protein Ubiquitin. The company says Affilin molecules are high affinity binders with